LONGBIO-B

LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues,organs and indications. The company was founded in 2020 and is based in Changshu, China.